Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sharp TherapeuticsSHRXF 12 EV-to-OCF is -4.73 as of Sep. 04, 2026. GuruFocus rates SHRXF with a GF Score™ of 12/100. Among 1,408 Biotechnology companies, Sharp Therapeutics ranks better than 55.33% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sharp Therapeutics's Enterprise Value is $22.83 Mil.
Sharp Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.83 Mil. Therefore, Sharp Therapeutics's EV-to-OCF for today is -4.73.
The historical rank and industry rank for Sharp Therapeutics's EV-to-OCF or its related term are showing as below:
SHRXF'
s EV-to-OCF Range Over the Past 10 Years
Min: -4.71 Med: 0 Max: -4.71
Current: -4.71
During the past 3 years, the highest EV-to-OCF of Sharp Therapeutics was -4.71. The lowest was -4.71. And the median was .
SHRXF's EV-to-OCF is ranked better than 55.33% of 1408
companies
in the Biotechnology industry
Industry Median: -3.68
vs SHRXF: -4.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sharp Therapeutics's PE Ratio (TTM) for today is calculated as:
Sharp Therapeutics's share price for today is $0.5691.
Sharp Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sharp Therapeutics EV-to-OCF Related Terms
Sharp Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sharp Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sharp Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sharp Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sharp Therapeutics's EV-to-OCF falls into.
Sharp Therapeutics's current Enterprise Value is $22.83 Mil.
Sharp Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sharp Therapeutics (SHRXF) has a EV-to-OCF of -4.73 as of Sep. 04, 2026. According to the industry distribution chart, Sharp Therapeutics ranks #629 out of 1408 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Sharp Therapeutics' EV-to-OCF too high?
Sharp Therapeutics' current EV-to-OCF is -4.73. Based on the distribution chart, Sharp Therapeutics ranks #629 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sharp Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sharp Therapeutics ranks #629 out of 1408 companies for EV-to-OCF. This puts Sharp Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sharp Therapeutics's current EV-to-OCF is -4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (SHRXF) has a current EV-to-OCF of -4.73. The current EV-to-OCF is -4.73. Sharp Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sharp Therapeutics (SHRXF), the current EV-to-OCF is -4.73 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
12GF Score
Get the complete analysis for SHRXF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHRXF has been successfully added to your 
